CWA
MYGN icon

Clarus Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

Clarus Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,890
Closed -$232K – 132
2024
Q3 		$232K Sell
8,890
-932
-9% -$25.2K 0.12% 115
2024
Q2 		$247K Buy
+9,822
New +$216K 0.13% 110
2024
Q1 		– Sell
-10,119
Closed -$204K – 139
2023
Q4 		$204K Buy
+10,119
New +$175K 0.12% 116
2019
Q3 		– Sell
-3,393
Closed -$94K – 413
2019
Q2 		$94K Buy
3,393
+1,893
+126% +$53.5K 0.07% 202
2019
Q1 		$50K Hold
1,500
– – 0.04% 290
2018
Q4 		$44K Hold
1,500
– – 0.07% 278
2018
Q3 		$69K Hold
1,500
– – 0.05% 255
2018
Q2 		$44K Buy
+1,500
New +$50.7K 0.03% 304

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Clarus Wealth Advisors's MYGN Position: Q4 2024 in Review

Clarus Wealth Advisors sold out of Myriad Genetics (MYGN) in Q4 2024, closing a stake of 8,890 shares — an estimated $232K sold.

Clarus Wealth Advisors first reported a position in MYGN in Q2 2018 and held it in 8 quarters. The position peaked at $247K in Q2 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q4 2024.

  • Clarus Wealth Advisors reported no remaining Myriad Genetics position as of Q4 2024 after selling out during the quarter.
  • Clarus Wealth Advisors sold 8,890 Myriad Genetics shares in Q4 2024, an estimated $232K.
  • Clarus Wealth Advisors first reported a position in Myriad Genetics in Q2 2018 and held it in 8 quarters.
  • Clarus Wealth Advisors's Myriad Genetics position peaked at $247K in Q2 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2024.

Based on Clarus Wealth Advisors's 13F filing for Q4 2024, filed 14 Jan 2025.